Pay in 4 interest-free payments of $5.37 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Candidates who typically benefit most from semaglutide therapy include individuals with obesity (defined medically as a body mass index of 30 or higher) or those who are overweight (with a BMI of 27 or higher) and experiencing weight-related health conditions such as elevated cholesterol, diabetes, or high blood pressure
Get it right, and you pave the way for clear, reliable data
Complete an online assessment Provide relevant health and treatment information Your submission is reviewed for suitability If appropriate, further guidance will be provided General information only Suitability is reviewed individually Not everyone will be suitable Approval is not guaranteed No specific outcome is promised Suitability depends on the information provided during your assessment
Incretin-Based Glucose-Lowering Medications and the Risk of Acute Pancreatitis and Malignancies: A Meta-Analysis Based on Cardiovascular Outcomes Trials
Obrador, E., & Estrela, J
Understanding who is a candidate for GLP-1 helps ensure the right individuals receive the most benefit while minimizing risk
